Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: A retrospective study

Cancer

Volumn 112, Issue 5, 2008, Pages 1147-1152

  Di Lorenzo, Giuseppe ^a   Di Trolio, Rossella ^a   Montesarchio, Vincenzo ^b   Palmieri, Giovanna ^a,c   Nappa, Paola ^a   Delfino, Mario ^a   De Placido, Sabino ^a   Dezube, Bruce J ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^c Villa Maria Hospital   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Classic Kaposi sarcoma; Pegylated liposomal doxorubicin; Second line treatment

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DOXORUBICIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HUMANS; MALE; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 39749193609     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23264     Document Type: Article

References (22)

1. Krown SE. Clinical overview: issues in Kaposi's sarcoma therapeutics. J Natl Cancer Inst Monogr. 1998;23:59-63.
2. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol. 1993;28:371-395.
3. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865-1869.
4. Brambilla L, Miedico A, Ferrucci S, et al. Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol. 2006;20:1090-1094.
5. Tur E, Brenner S. Classic Kaposi's sarcoma: low-dose interferon alfa treatment. Dermatology. 1998;197:37-42.
6. Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposi's sarcoma with paclitaxel. Anticancer Res. 2001;21:571-573.
7. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer. 1994;74:2873-2878.
8. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 2007;8:167-176.
9. Di Trolio R, Di Lorenzo G, Delfino M, De Placido S. Role of pegylated liposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. Int J Immunopathol Pharmacol. 2006;19:253-263.
10. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445-2451.
11. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma.International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683-691.
12. Gottlieb J, Washenik K, Chachoua A, Friedman-Kien A. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet. 1997;350:1363-1364.
13. Danopoulou I, Paprizos V, Dimopoulou S, et al. Successful treatment of a patient with classic Kaposi's sarcoma and chronic lymphocytic leukemia with liposomal doxorubicin. Ann Dermatol Venereol. 2002;129:1-3.
14. Ezquerra GM, Redonnet MS, Cuchillero RO, Millet PU. Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy. J Eur Acad Dermatol Venereol. 2006;20:901-902.
15. Kreuter A, Rasokat H, Mouche M, et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma: retrospective analysis of 3 German centers. Cancer Invest. 2005;23:653-659.
16. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. 2003;13:83-86.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
18. National Cancer Institute. Common Toxicity Criteria for Adverse Events. Version 3.0. Bethesda, MD: National Cancer Institute; 2003.
19. Dudgeon D, Raubertas RF, Rosenthal SN. The short-form McGill Pain Questionnaire in chronic cancer pain. J Pain Symptom Manage. 1993;8:191-195.
20. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spinal cells. Nat Med. 1995;1:1274-1278.
21. Brambilla L, Labianca R, Ferrucci SM, Taglioni M, Boneschi V. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology. 2001;202:119-122.
22. Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer. 2006;106:1785-1789.